2019 VORONOI Symposium…Domestic and foreign drug development experts participated - hankyung.com At the symposium held at the Westin Chosun Hotel in Seoul on May 14th, under the slogan of 'from basics to clinical', domestic and foreign drug development experts participated and shared the latest trends in academia. 기사 전문보기
Dana-Farber Cancer Institute grants exclusive right of protein degradation patent to Voronoi-AsiaBiz View the update
BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada
Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.
Scientific Advisor: Lillian L. Siu, M.D. BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). She currently serves on the AACR Board of Directors for a three-year term (2017-2020). Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine. Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010. Locally, she was awarded the University of Toronto Department of Medicine Eaton Scholar Researcher in 2016. She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She was Chairperson of the AACR Education Committee, Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting and Co-Chairperson for the Clinical Trials Committee 2015-2017. Dr. Siu has published over 300 peer-reviewed manuscripts, and she is currently a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology. Lillian L. Siu, M.D. BMO Chair in Precision Genomics Professor of Medicine, Princess Margaret Cancer Centre, Toronto, Canada Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer
Scientific Advisor: Pasi A. Jänne, M.D.,Ph.D. Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University. Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. Dr. Jänne has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. Dr. Jänne is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award, a member of the 2010 AACR Team Science Award and the recipient for the 2018 Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. He is an elected member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish Academy of Science and Letters (2016). In 2017 he was awarded an American Cancer Society Clinical Research Professorship and in 2018 the European Society of Medical Oncology Translational Research Award and the Outstanding Investigator Award (R35) from the National Cancer Institute. Pasi A. Jänne, M.D.,Ph.D. Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002, he earned a Masters Degree in clinical investigation from Harvard University. Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance
Patent attorney KIM & CHANG Seoul National University, B.S. Lim Jaeyoung / Intellectual Property I worked as a patent attorney in Kim&Chang law firm after graduating School of Chemical and Biological Engineering in Seoul National University. Currently, I am leading Intellectual Property team at Voronoi. "I had been leading many cases on patent and intellectual property on behalf of global leading companies including pharmaceutical companies. Especially, I was handling many IP M&A cases including IP due diligence and freedom-to-operate analysis. Also I worked at JunHe, the Chinese law firm, and handled many cases on China IP issue. Based on this experience, I am currently leading IP team and building IP strategy in Voronoi to protect our valuable assets in pipeline and maximize the value of them. The importance of intellectual property in pharmaceutical and biology area is never too high. In order to protect and increase the value of assets in pipeline, protecting IP rights and designing IP strategies is essential. I will do my best to maximize Voronoi’s pipeline values through IP management." Patent attorney KIM & CHANG Seoul National University, B.S. Lim Jaeyoung / Intellectual Property I worked as a patent attorney in Kim&Chang law firm after graduating School of Chemical and Biological Engineering in Seoul National University. Currently, I am leading Intellectual Property team at Voronoi. "I had been leading many cases on patent and intellectual property on behalf of global leading companies including pharmaceutical companies. Especially, I was handling many IP M&A cases including IP due diligence and freedom-to-operate analysis. Also I worked at JunHe, the Chinese law firm, and handled many cases on China IP issue. Based on this experience, I am currently leading IP team and building IP strategy in Voronoi to protect our valuable assets in pipeline and maximize the value of them. The importance of intellectual property in pharmaceutical and biology area is never too high. In order to protect and increase the value of assets in pipeline, protecting IP rights and designing IP strategies is essential. I will do my best to maximize Voronoi’s pipeline values through IP management."
(前) DB자산운용, 퀀트운용 서울대학교 수리과학부, 학사 Lee Kyungho /AI and Applied Mathematics We aim to develop platform for new drug development through applying machine learning technology. "Machine learning is applied to a variety of areas such as image recognition, voice regonition, autonomous driving, etc. Recently, it is being applied to life sciences as well and prediction in protein folding which shows better performance than existing method is one of the representative cases. AI Lab aims to develop machine learning model that is specifically designed for new drug development. We are continuing our research and development in creating the effective solution to all possible problems in the journey of new drug development. There is not much data accumulated in this field and therefore, it is critical to effectively and efficiently analyze and use the data and knowledge we have in hand. We are using unsupervised learning method and with more data to come from Voronoi scientists and R&D team, we expect to improve our AI development platform. I had been working at finance industry, specifically focusing on quantitative investing for the last 10 years. Currently, I am applying my experience to new drug development in Voronoi AI lab." (前) DB자산운용, 퀀트운용 서울대학교 수리과학부, 학사 Lee Kyungho /AI and Applied Mathematics We aim to develop platform for new drug development through applying machine learning technology. "Machine learning is applied to a variety of areas such as image recognition, voice regonition, autonomous driving, etc. Recently, it is being applied to life sciences as well and prediction in protein folding which shows better performance than existing method is one of the representative cases. AI Lab aims to develop machine learning model that is specifically designed for new drug development. We are continuing our research and development in creating the effective solution to all possible problems in the journey of new drug development. There is not much data accumulated in this field and therefore, it is critical to effectively and efficiently analyze and use the data and knowledge we have in hand. We are using unsupervised learning method and with more data to come from Voronoi scientists and R&D team, we expect to improve our AI development platform. I had been working at finance industry, specifically focusing on quantitative investing for the last 10 years. Currently, I am applying my experience to new drug development in Voronoi AI lab."
Seoul National University, B.S. Fast growth "For Voronoi, it only takes 1.5 years to develop a new drug candidate." For Voronoi, it only takes 1.5 years to develop a new drug candidate while it usually takes 4.5 years in the industry average. The speed is exceptionally high. The reason for this high speed is because we, Voronoi, have many talents and professional experts who majored in molecular modeling, medicinal chemistry, and kinase inhibitor development. Each of them are Dr. Kim, Dr. Choi, and Dr. Gray. They all have previous experience of creating and developing novel small molecule drugs and out-licensing them to global leading pharmaceutical companies. I am proud that I can be also part of this team and the company, learning from them. There are much more to catch up. My job definitely requires fast learning speed. Collaboration "Effective partnership" Voronoi is collaborating with Dana-Farber Cancer Institute, Yonsei University Medical School, Korea Brain Research Institute, National Cancer Center, etc. We also have Dr. Janne of Harvard Medical School as our scientific advisory board for our lung cancer pipeline. We frequently have a discussion with our partners and advisors. Collaboration does not only apply to external partners, but also to internal teams. Voronoi pursue open-minded and respecting working culture and we aim to have effective discussion between teams and divisions. If you can lead effective meetings with bright energy, you will find yourself so fit into our culture. Work & Life balance "Flexible and Efficient" Voronoi pursues flexible and efficient working culture. You don’t need to sit on the chair only to show your presence. Suppose you have personal appointments and want to leave office early. You can always do so if you are done with your work. We give ownership and responsibility to each employee with huge trust. You can find flexible working culture here in Voronoi.
